Skip Ribbon Commands
Skip to main content
 
Cellular Therapy & Immunobiology

Introduction 

The mission of the Cellular Therapy & Immunobiology Working Party is to understand and exploit the biological including immunological events occurring upon haematopoietic stem cell transplantation at large, and to implement modern cellular therapies based on cell and gene engineering approaches to improve transplantation outcomes.

Cellular Therapy is an emerging medical science that is today facing a unique developmental phase, well documented by the outstanding and growing numbers of clinical trials. Such an exponential growth requires proper infrastructures, cell repositories, clinical registries, technical and regulatory guidelines for appropriate cell manipulation and validation of the innovative therapeutic approaches in multicentric clinical trials.

The CTIWP aims at fostering cellular therapy in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of cellular manufacturing approaches designed to answer unmet medical needs.

To this aim we will actively implement:

  1. Retrospective and multicentric prospective transplant immunobiology studies
  2. Retrospective and multicentric prospective clinical trials of cell/gene therapy
  3. A map of European Centers active in cell manipulation and cell therapy
  4. A dedicated registry for cellular products and clinical trials of cell and cell-based gene therapy.

These aims will be pursued through the activity of WP subcommittees and through an active collaboration with International and European Societies of Transplantation, Cell/Gene Therapy and with major investors in the field.

Meetings

Educational Event of CMWP and CTIWP: "Come of age : Immunotherapy in Multiple Myeloma”. 30 September to 1 October 2016 in Berlin, Germany
 

Members   

Chairperson
Chiara Bonini
bonini.chiara@hsr.it 
 
 
 
 

 
Secretary
Christian Chabannon
CHABANNONC@ipc.unicancer.fr 
 
 
 
 
 
 

The CTIWP studies are allocated to the EBMT Data Office Leiden:

​Steffie van der Werf​ ​Study Coordinator​ S.M.van_der_Werf@lumc.nl
 

Subcommitte Leaders:

​Antoine Toubert​ ​Transplant Immunobiology
Annalisa Ruggeri​ ​Cord blood immunobiology
Attilio Bondanza​ ​Cancer immunotherapy
​Katharina Fleischhauer
Vanderson Rocha
​Immunogenetics
Francesco Dazzi​ ​Immune tolerance
​​Paolo Pedrazzoli ​Solid Tumor
 

survey

Immune reconstitution

Survey to evaluate and summarize advances in immune recovery after allogeneic HSCT, focusing on the recovered immune subsets likely to have the greatest impact on clinical outcomes. We would appreciate if you could answer to the following questions in appendix-I, to help us designing a proper retrospective study concerning the monitoring of post-transplant immune reconstitution.
 

Related documents

Click HERE to view the publication list

 HLA identification page for the two combined retrospective studies on haploidentical stem cell transplantation in AML and ALL 


Studies coordinated by the CTIWP

Click HERE to view the Current Research list

How to get involved?

Please contact the Chairperson or the Secretary.​

 

 News

 
15/11/2017
November 2017 | Vol. 59 - Issue 5 ... Read more >>
18/10/2017
​vaccinations and CMV/HHV6 infections post-HSCT​... Read more >>
17/05/2017
The EBMT implements Elsevier’s MACRO platform to upgrade patient registry.... Read more >>
10/05/2016
​More than 60 EBMT centres have already started entering their related donor data. We want to invite... Read more >>
 

 Events

 
Bookmark and Share